Clinical Trial Update: CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating the combination of cytokine-induced killer (CIK) cell transfusion with gefitinib as second- or third-line therapy for advanced non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CIK cell transfusion (cytokine-induced killer cells)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Kunming Medical University | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED